Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.
aptamer technology
connective tissue disease
immunology
interstitial lung disease
proteomics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
06
2023
accepted:
28
08
2023
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Systemic sclerosis (SSc) is an autoimmune connective tissue disease that affects multiple organs, leading to elevated morbidity and mortality with limited treatment options. The early detection of organ involvement is challenging as there is currently no serum marker available to predict the progression of SSc. The aptamer technology proteomic analysis holds the potential to correlate SSc manifestations with serum proteins up to femtomolar concentrations. This is a two-tier study of serum samples from women with SSc (including patients with interstitial lung disease - ILD - at high-resolution CT scan) and age-matched healthy controls (HC) that were first analyzed with aptamer-based proteomic analysis for over 1300 proteins. Proposed associated proteins were validated by ELISA first in an independent cohort of patients with SSc and HC, and selected proteins subject to further validation in two additional cohorts. The preliminary aptamer-based proteomic analysis identified 33 proteins with significantly different concentrations in SSc compared to HC sera and 9 associated with SSc-ILD, including proteins involved in extracellular matrix formation and cell-cell adhesion, angiogenesis, leukocyte recruitment, activation, and signaling. Further validations in independent cohorts ultimately confirmed the association of specific proteins with early SSc onset, specific organ involvement, and serum autoantibodies. Our multi-tier proteomic analysis identified serum proteins discriminating patients with SSc and HC or associated with different SSc subsets, disease duration, and manifestations, including ILD, skin involvement, esophageal disease, and autoantibodies.
Sections du résumé
Background
Systemic sclerosis (SSc) is an autoimmune connective tissue disease that affects multiple organs, leading to elevated morbidity and mortality with limited treatment options. The early detection of organ involvement is challenging as there is currently no serum marker available to predict the progression of SSc. The aptamer technology proteomic analysis holds the potential to correlate SSc manifestations with serum proteins up to femtomolar concentrations.
Methods
This is a two-tier study of serum samples from women with SSc (including patients with interstitial lung disease - ILD - at high-resolution CT scan) and age-matched healthy controls (HC) that were first analyzed with aptamer-based proteomic analysis for over 1300 proteins. Proposed associated proteins were validated by ELISA first in an independent cohort of patients with SSc and HC, and selected proteins subject to further validation in two additional cohorts.
Results
The preliminary aptamer-based proteomic analysis identified 33 proteins with significantly different concentrations in SSc compared to HC sera and 9 associated with SSc-ILD, including proteins involved in extracellular matrix formation and cell-cell adhesion, angiogenesis, leukocyte recruitment, activation, and signaling. Further validations in independent cohorts ultimately confirmed the association of specific proteins with early SSc onset, specific organ involvement, and serum autoantibodies.
Conclusions
Our multi-tier proteomic analysis identified serum proteins discriminating patients with SSc and HC or associated with different SSc subsets, disease duration, and manifestations, including ILD, skin involvement, esophageal disease, and autoantibodies.
Identifiants
pubmed: 37753072
doi: 10.3389/fimmu.2023.1246777
pmc: PMC10518467
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1246777Informations de copyright
Copyright © 2023 Motta, Tonutti, Isailovic, Ceribelli, Costanzo, Rodolfi, Selmi and De Santis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Postepy Dermatol Alergol. 2019 Jun;36(3):325-338
pubmed: 31333350
Eur J Intern Med. 2019 Feb;60:46-53
pubmed: 30366614
Respir Med. 2022 Jan;191:106689
pubmed: 34844174
Z Rheumatol. 2017 Nov;76(9):789-797
pubmed: 27515182
Curr Opin Pharmacol. 2001 Jun;1(3):248-53
pubmed: 11712747
Int Immunopharmacol. 2020 Mar;80:106223
pubmed: 31991374
Ann Rheum Dis. 2023 Mar;82(3):365-373
pubmed: 36600187
Sci Rep. 2019 Aug 6;9(1):11382
pubmed: 31388062
Int Immunopharmacol. 2022 May;106:108608
pubmed: 35180626
Blood. 2017 Nov 9;130(19):2092-2100
pubmed: 28807980
J Immunol. 2022 Jul 15;209(2):199-207
pubmed: 35821102
Science. 2016 Oct 21;354(6310):358-362
pubmed: 27846573
J Pathol. 2006 Oct;210(2):240-8
pubmed: 16917801
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Biomed Res Int. 2018 Mar 12;2018:3921247
pubmed: 29721505
Rheumatology (Oxford). 2008 Dec;47(12):1754-60
pubmed: 18829709
Mod Rheumatol. 2013 Sep;23(5):884-90
pubmed: 22972016
Proteomics. 2014 Mar;14(6):638-44
pubmed: 24395722
Arthritis Res Ther. 2018 Aug 16;20(1):185
pubmed: 30115106
N Engl J Med. 2015 Nov 12;373(20):1977-8
pubmed: 26559581
Gut. 2018 Jun;67(6):1052-1063
pubmed: 28468761
J Dermatol Sci. 2018 Apr;90(1):52-59
pubmed: 29336866
J Proteomics. 2013 May 27;83:60-75
pubmed: 23528693
Int J Rheum Dis. 2012 Aug;15(4):374-9
pubmed: 22898217
J Rheumatol. 2010 Sep;37(9):1852-7
pubmed: 20595276
Semin Arthritis Rheum. 2023 Feb;58:152126
pubmed: 36434895
J Rheumatol. 2017 May;44(5):631-638
pubmed: 28298564
Sci Rep. 2018 Mar 23;8(1):5085
pubmed: 29572462
Ann Rheum Dis. 2012 Jun;71(6):1064-72
pubmed: 22258486
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Annu Rev Immunol. 2015;33:747-85
pubmed: 25706098
Clin Rev Allergy Immunol. 2023 Jun;64(3):412-430
pubmed: 35716254
Int J Mol Sci. 2020 Dec 15;21(24):
pubmed: 33333969
Rheumatology (Oxford). 2018 Oct 1;57(10):1698-1706
pubmed: 29140474
Clin Rheumatol. 2014 Mar;33(3):335-9
pubmed: 24370646
Int J Mol Sci. 2019 Mar 06;20(5):
pubmed: 30845706
Circulation. 2016 Jul 26;134(4):286-9
pubmed: 27444931
Front Immunol. 2021 Nov 16;12:766586
pubmed: 34868019
Lancet. 2023 Jan 28;401(10373):304-318
pubmed: 36442487
Am J Respir Cell Mol Biol. 2007 Aug;37(2):210-21
pubmed: 17446527
Curr Opin Rheumatol. 2019 Nov;31(6):595-602
pubmed: 31436584
Nat Rev Rheumatol. 2019 May;15(5):288-302
pubmed: 30953037
J Inflamm (Lond). 2006 Feb 22;3:2
pubmed: 16504062
Curr Opin Rheumatol. 2014 Nov;26(6):646-52
pubmed: 25203118
Ann Rheum Dis. 2012 Jul;71(7):1227-34
pubmed: 22696687
Am J Respir Cell Mol Biol. 2004 Aug;31(2):220-6
pubmed: 15039135
Arthritis Res Ther. 2022 Dec 24;24(1):280
pubmed: 36564791
Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):240-248
pubmed: 31464680
Isr Med Assoc J. 2019 Sep;21(9):620-623
pubmed: 31542909
Inflammation. 2019 Apr;42(2):463-470
pubmed: 30680696
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
J Invest Dermatol. 2014 Sep;134(9):2321-2330
pubmed: 24496236
N Engl J Med. 2021 Dec 16;385(25):2361-2376
pubmed: 34910865
Ann Rheum Dis. 2014 Jul;73(7):1340-9
pubmed: 23687283
N Engl J Med. 2009 May 7;360(19):1989-2003
pubmed: 19420368
Cytokine. 2017 Oct;98:51-58
pubmed: 27916613
Rheumatology (Oxford). 2019 Jan 1;58(1):165-178
pubmed: 30239835
PLoS One. 2021 Feb 22;16(2):e0247256
pubmed: 33617568
Am J Pathol. 2013 Apr;182(4):1286-96
pubmed: 23490254
Arthritis Res Ther. 2011;13(5):R166
pubmed: 21996293
Ann Rheum Dis. 2017 Aug;76(8):1327-1339
pubmed: 27941129
Transplant Proc. 2010 Sep;42(7):2763-6
pubmed: 20832583
Rheumatology (Oxford). 2020 Jun 1;59(6):1416-1425
pubmed: 31899518
Rheumatol Int. 2023 Feb;43(2):345-354
pubmed: 36416900
J Invest Dermatol. 2017 Jan;137(1):62-70
pubmed: 27640094
PLoS One. 2022 Dec 22;17(12):e0279461
pubmed: 36548367
PLoS One. 2016 Jun 16;11(6):e0157376
pubmed: 27310888
Curr Opin Rheumatol. 2019 May;31(3):241-249
pubmed: 30870216
Arthritis Res Ther. 2023 Jan 27;25(1):15
pubmed: 36707842
N Engl J Med. 2014 Jan 30;370(5):433-43
pubmed: 24350901
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Mucosal Immunol. 2020 Jan;13(1):64-74
pubmed: 31597930
Expert Rev Proteomics. 2017 May;14(5):431-444
pubmed: 28425787
Eur Respir J. 2021 Jun 24;57(6):
pubmed: 33334933
Arthritis Rheumatol. 2023 Aug;75(8):1424-1433
pubmed: 36908055
Rheumatology (Oxford). 2011 Apr;50(4):746-55
pubmed: 21149250
Ann Rheum Dis. 2016 Sep;75(9):1697-705
pubmed: 26452537